Pharmaceuticals

Previously, Benzinga reported that Jefferies previewed Watson Pharmaceuticals' (NYSE: WPI) investor day. This information is incorrect. We apologize for any inconvenience. We have retracted the article from our site.

• Share prices of tech major IBM (NYSE:IBM) rose by 3.35% after the company posted excellent earnings figure on Tuesday night • Adtran Inc (NASDAQ:ADTN) increased 6.56% to end at $42.25 after the company posted an  increased sales figures for the fourth quarter that came in above expectations • ...

MannKind Corp. (MNKD) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for its new drug application (NDA) for type I and type II diabetes treatment Afrezza. MannKind's share price plummeted 44% in after hours trading,...

Labopharm Inc. (NASDAQ: DDSS) today announced that Health Canada's Therapeutic Products Directorate has approved OLEPTRO for the symptomatic relief of Major Depressive Disorder in adults. OLEPTRO acts as a serotonin antagonist reuptake inhibitor, providing physicians and patients in Canada with a...

MannKind Corp. (MNKD) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for its new drug application (NDA) for type I and type II diabetes treatment Afrezza. MannKind's share price plummeted 44% in after hours trading,...

Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the pricing of a previously announced underwritten public offering of 2,750,000 shares of its common stock, offered at a price to the public of $26.00 per share. The gross proceeds to Ardea from this offering are expected to be $71,500,000...

• Share prices of tech major IBM (NYSE:IBM) rose by 3.35% after the company posted excellent earnings figure on Tuesday night • Adtran Inc (NASDAQ:ADTN) increased 6.56% to end at $42.25 after the company posted an  increased sales figures for the fourth quarter that came in above expectations • ...

Perrigo Company (Nasdaq: PRGO) today announced that it has signed a definitive agreement to acquire substantially all of the assets of Paddock Laboratories, Inc.. for approximately $540 million in cash. Perrigo expects to receive a significant tax benefit as a result of the acquisition of Paddock's...

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief for its New Drug Application for Lamivudine and Zidovudine Tablets, 30 mg/60...

Leading health care products maker Covidien plc (COV) has introduced its EverFlex+ self-expanding peripheral stent system in Europe. The new system represents the advanced version of the company's EverFlex stent technology for treating peripheral arterial disease. The launch underscores Covidien'...

Leading health care products maker Covidien plc (COV) has introduced its EverFlex+ self-expanding peripheral stent system in Europe. The new system represents the advanced version of the company's EverFlex stent technology for treating peripheral arterial disease. The launch underscores Covidien'...

Market Folly has just posted David Einhorn's 2010 year end letter. Einhorn is a noted value investor who runs hedge fund Greenlight Capital. In the letter, Einhorn discloses new stakes in BP (NYSE: BP) and Sprint (NYSE: S). The fund's top five holdings are Arkema (PINK:ARKAY), Ensco (NYSE: ESV),...

Merck (NYSE: MRK) (known outside the United States and Canada as MSD) reported today that investigators in the TRA-2P study of vorapaxar have been provided with additional information about the recommendations of the Data and Safety Monitoring Board (DSMB) regarding the TRA-2P study. The additional...

Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it has commenced an underwritten public offering of an aggregate of 2,500,000 shares of its common stock. In connection with this offering, Ardea plans to grant to the underwriters a 30-day option to purchase up to an additional 375,000...

Ariad Pharmaceuticals Inc.'s (ARIA) pipeline received a boost when its lead cancer candidate ridaforolimus fared well in a late-stage study, SUCCEED. Ridaforolimus has been licensed to Merck & Co. (MRK) and is being developed as a treatment for cancer. The study evaluated the candidate in...